Progression-free survival (PFS) is defined as the time from randomization to the date of the first documented tumor progression, as determined by investigators (per RECIST v1.1), or death due to any cause, whichever occurs first.

All randomized participants in Groups A-D only

Overall survival (OS) is defined as the time from randomization to the date of death.

All randomized participants in Groups A-C only

Percentage of participants who experienced a treatment-related AE during the course of the study that lead to discontinuation of both study drugs.

All treated participants in Group E only

Duration of response (DOR) is defined as the time from first confirmed response (complete response (CR) or partial response (PR)) to the date of the initial objectively documented tumor progression as determined using RECIST 1.1 criteria or death due to any cause, whichever occurs first.

Median computed using Kaplan-Meier method.

All responders (participants with objective response of CR or PR) in Groups A-D only.

Objective response rate (ORR) is defined as the number and percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR). Best overall response (BOR) is defined as the best response designation, recorded between the date of first dose and the date of the initial objectively documented tumor progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.

Confidence interval based on the Clopper and Pearson method.

All randomized (Groups A-D) and treated (Group E) participants with at least one lesion at baseline

Overall survival (OS) is defined as the time from randomization to the date of death.

All randomized participants in Group D only

Progression-free survival (PFS) is defined as the time from randomization to the date of the first documented tumor progression, as determined by investigators (per RECIST v1.1), or death due to any cause, whichever occurs first.

All treated participants in Group E only